Rockwell Medical (RMTI) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

RMTI Stock Forecast

Rockwell Medical stock forecast is as follows: an average price target of $9.00 (represents a 309.09% upside from RMTI’s last price of $2.20) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

RMTI Price Target

The average price target for Rockwell Medical (RMTI) is $9.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $9.00. This represents a potential 309.09% upside from RMTI's last price of $2.20.

RMTI Analyst Ratings

Buy

According to 1 Wall Street analysts, Rockwell Medical's rating consensus is 'Buy'. The analyst rating breakdown for RMTI stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Rockwell Medical Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 04, 2024	Raghuram Selvaraju	H.C. Wainwright	-	-	181.91%	309.09%
Jul 17, 2023	Raghuram Selvaraju	H.C. Wainwright	-	-	162.53%	400.00%

Row per page

Go to

The latest Rockwell Medical stock forecast, released on Sep 04, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $9.00, which represents a 181.91% increase from the stock price at the time of the forecast ($3.19), and a 309.09% increase from RMTI last price ($2.20).

Rockwell Medical Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	1
Avg Price Target	-	$9.00	$9.00
Last Closing Price	$2.20	$2.20	$2.20
Upside/Downside	-100.00%	309.09%	309.09%

In the current month, the average price target of Rockwell Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rockwell Medical's last price of $2.20. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 04, 2024	H.C. Wainwright	Buy	Buy	Hold
Jul 17, 2023	H.C. Wainwright	Buy	Buy	Hold

Row per page

Go to

Rockwell Medical's last stock rating was published by H.C. Wainwright on Sep 04, 2024. The company gave RMTI a "Buy" rating, the same as its previous rate.

Rockwell Medical Financial Forecast

Rockwell Medical Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$23.77M	-	$19.67M	$19.31M	$18.69M	$18.68M	$16.12M	$45.94M	$15.99M	$15.14M	$15.47M	$15.16M	$15.28M	$15.90M	$15.86M	$15.49M	$15.41M	$14.85M	$15.56M	$14.95M	$14.59M
Avg Forecast	$24.27M	$23.65M	$23.19M	$21.92M	$24.07M	$26.50M	$22.91M	$21.70M	$22.63M	$22.85M	$18.08M	$19.12M	$16.30M	$19.37M	$16.80M	$18.80M	$17.65M	$18.18M	$18.22M	$17.24M	$15.66M	$15.67M	$14.41M	$15.55M	$16.22M	$15.98M	$16.39M	$16.90M	$19.03M	$12.97M
High Forecast	$25.29M	$24.64M	$24.16M	$22.85M	$25.08M	$26.50M	$22.91M	$22.62M	$23.59M	$22.85M	$18.84M	$19.92M	$16.99M	$19.37M	$16.80M	$18.80M	$17.65M	$18.18M	$18.22M	$17.24M	$15.66M	$15.67M	$14.41M	$15.55M	$16.22M	$15.98M	$16.39M	$16.90M	$22.83M	$15.57M
Low Forecast	$23.24M	$22.65M	$22.21M	$21.00M	$23.06M	$26.50M	$22.91M	$20.79M	$21.68M	$22.85M	$17.31M	$18.31M	$15.61M	$19.37M	$16.80M	$18.80M	$17.65M	$18.18M	$18.22M	$17.24M	$15.66M	$15.67M	$14.41M	$15.55M	$16.22M	$15.98M	$16.39M	$16.90M	$15.22M	$10.38M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	10
Surprise %	-	-	-	-	-	-	-	-	-	1.04%	-	1.03%	1.18%	0.96%	1.11%	0.86%	2.60%	0.88%	0.83%	0.90%	0.97%	0.97%	1.10%	1.02%	0.95%	0.96%	0.91%	0.92%	0.79%	1.13%

Rockwell Medical's average Quarter revenue forecast for Dec 23 based on 1 analysts is $22.63M, with a low forecast of $21.68M, and a high forecast of $23.59M. RMTI's average Quarter revenue forecast represents a -4.78% decrease compared to the company's last Quarter revenue of $23.77M (Sep 23).

Rockwell Medical EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	10
EBITDA	-	-	-	-	-	-	-	-	-	$-1.74M	-	$-1.20M	$-1.92M	$-3.07M	$-3.83M	$-5.97M	$-31.42M	$-7.66M	$-7.19M	$-6.56M	$1.17M	$-6.14M	$-5.82M	$-7.28M	$-6.66M	$-7.20M	$-9.60M	$-8.01M	$-6.40M	$-4.61M
Avg Forecast	$-8.11M	$-7.90M	$-7.74M	$-7.32M	$-8.04M	$-8.85M	$-7.65M	$-6.00M	$-7.56M	$-7.63M	$-6.04M	$-6.42M	$-37.40M	$-6.69M	$-5.81M	$-6.87M	$-6.10M	$-6.28M	$-6.29M	$-7.29M	$-5.41M	$-5.42M	$-4.98M	$-7.28M	$-5.61M	$-5.52M	$-5.66M	$-9.35M	$-7.77M	$-4.04M
High Forecast	$-7.76M	$-7.57M	$-7.42M	$-7.01M	$-7.70M	$-8.85M	$-7.65M	$-4.80M	$-7.24M	$-7.63M	$-5.78M	$-5.14M	$-29.92M	$-6.69M	$-5.81M	$-5.49M	$-6.10M	$-6.28M	$-6.29M	$-5.83M	$-5.41M	$-5.42M	$-4.98M	$-5.83M	$-5.61M	$-5.52M	$-5.66M	$-7.48M	$-6.22M	$-3.23M
Low Forecast	$-8.45M	$-8.23M	$-8.07M	$-7.63M	$-8.38M	$-8.85M	$-7.65M	$-7.20M	$-7.88M	$-7.63M	$-6.29M	$-7.71M	$-44.88M	$-6.69M	$-5.81M	$-8.24M	$-6.10M	$-6.28M	$-6.29M	$-8.74M	$-5.41M	$-5.42M	$-4.98M	$-8.74M	$-5.61M	$-5.52M	$-5.66M	$-11.22M	$-9.33M	$-4.84M
Surprise %	-	-	-	-	-	-	-	-	-	0.23%	-	0.19%	0.05%	0.46%	0.66%	0.87%	5.15%	1.22%	1.14%	0.90%	-0.22%	1.13%	1.17%	1.00%	1.19%	1.30%	1.70%	0.86%	0.82%	1.14%

1 analysts predict RMTI's average Quarter EBITDA for Mar 21 to be $-7.29M, with a high of $-5.83M and a low of $-8.74M. This is -724.65% lower than Rockwell Medical's previous annual EBITDA (Dec 20) of $1.17M.

Rockwell Medical Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	10
Net Income	-	-	-	-	-	-	-	-	-	$-1.87M	-	$-2.46M	$-2.75M	$-4.67M	$-5.45M	$-7.70M	$-35.03M	$-7.58M	$-8.40M	$-7.75M	$-8.66K	$-7.35M	$-6.89M	$-7.98M	$-7.30M	$-7.86M	$-10.29M	$-8.68M	$-6.53M	$-4.74M
Avg Forecast	$324.20K	$162.10K	$486.30K	$-648.40K	$486.30K	$324.20K	$-1.13M	$-7.21M	$-2.27M	$-3.40M	$-3.89M	$-7.71M	$-38.84M	$-15.54M	$-25.95M	$-8.25M	$-31.71M	$-26.43M	$-28.19M	$-8.61M	$-29.95M	$-35.24M	$-49.33M	$-7.98M	$-43.46M	$-56.38M	$-59.02M	$-10.12M	$-7.93M	$-4.15M
High Forecast	$341.97K	$170.99K	$512.96K	$-612.86K	$512.96K	$341.97K	$-1.07M	$-5.77M	$-2.15M	$-3.22M	$-3.68M	$-6.17M	$-31.07M	$-15.54M	$-25.95M	$-6.60M	$-31.71M	$-26.43M	$-28.19M	$-6.89M	$-29.95M	$-35.24M	$-49.33M	$-6.39M	$-43.46M	$-56.38M	$-59.02M	$-8.10M	$-6.34M	$-3.32M
Low Forecast	$306.43K	$153.22K	$459.65K	$-683.94K	$459.65K	$306.43K	$-1.20M	$-8.65M	$-2.39M	$-3.59M	$-4.10M	$-9.25M	$-46.61M	$-15.54M	$-25.95M	$-9.90M	$-31.71M	$-26.43M	$-28.19M	$-10.34M	$-29.95M	$-35.24M	$-49.33M	$-9.58M	$-43.46M	$-56.38M	$-59.02M	$-12.15M	$-9.51M	$-4.98M
Surprise %	-	-	-	-	-	-	-	-	-	0.55%	-	0.32%	0.07%	0.30%	0.21%	0.93%	1.10%	0.29%	0.30%	0.90%	0.00%	0.21%	0.14%	1.00%	0.17%	0.14%	0.17%	0.86%	0.82%	1.14%

Rockwell Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RMTI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Rockwell Medical SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	10
SG&A	-	-	-	-	-	-	-	-	-	$3.44M	-	$3.75M	$4.15M	$4.02M	$5.30M	$4.27M	$15.66M	$5.42M	$5.14M	$5.77M	$6.55M	$5.29M	$4.87M	$7.35M	$6.56M	$6.45M	$7.72M	$9.32M	$5.06M	$6.10M
Avg Forecast	$7.92M	$7.72M	$7.57M	$7.15M	$7.85M	$8.65M	$7.48M	$4.30M	$7.39M	$7.45M	$5.90M	$4.60M	$5.32M	$6.32M	$5.48M	$4.92M	$5.76M	$5.93M	$5.94M	$6.42M	$5.11M	$5.11M	$4.70M	$7.35M	$5.29M	$5.22M	$5.35M	$10.88M	$6.15M	$5.34M
High Forecast	$8.25M	$8.04M	$7.88M	$7.46M	$8.19M	$8.65M	$7.48M	$5.16M	$7.70M	$7.45M	$6.15M	$5.52M	$5.54M	$6.32M	$5.48M	$5.90M	$5.76M	$5.93M	$5.94M	$7.70M	$5.11M	$5.11M	$4.70M	$8.82M	$5.29M	$5.22M	$5.35M	$13.05M	$7.38M	$6.41M
Low Forecast	$7.58M	$7.39M	$7.25M	$6.85M	$7.52M	$8.65M	$7.48M	$3.44M	$7.07M	$7.45M	$5.65M	$3.68M	$5.09M	$6.32M	$5.48M	$3.94M	$5.76M	$5.93M	$5.94M	$5.13M	$5.11M	$5.11M	$4.70M	$5.88M	$5.29M	$5.22M	$5.35M	$8.70M	$4.92M	$4.27M
Surprise %	-	-	-	-	-	-	-	-	-	0.46%	-	0.81%	0.78%	0.64%	0.97%	0.87%	2.72%	0.91%	0.87%	0.90%	1.28%	1.03%	1.04%	1.00%	1.24%	1.24%	1.44%	0.86%	0.82%	1.14%

Rockwell Medical's average Quarter SG&A projection for Dec 23 is $7.39M, based on 1 Wall Street analysts, with a range of $7.07M to $7.70M. The forecast indicates a 114.39% rise compared to RMTI last annual SG&A of $3.44M (Sep 23).

Rockwell Medical EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	10
EPS	-	-	-	-	-	-	-	-	-	$-0.07	-	$-0.13	$-0.24	$-0.44	$-0.62	$-0.90	$-4.10	$-0.89	$-0.99	$-0.91	$-0.00	$-1.13	$-1.09	$-1.30	$-1.25	$-1.35	$-1.94	$-1.67	$-1.40	$-1.03
Avg Forecast	$0.01	$0.01	$0.01	$-0.02	$0.01	$0.01	$-0.04	$-0.04	$-0.07	$-0.10	$-0.12	$-0.17	$-0.39	$-0.48	$-0.81	$-0.99	$-0.99	$-0.82	$-0.88	$-0.99	$-0.94	$-1.10	$-1.54	$-1.43	$-1.36	$-1.76	$-1.84	$-1.98	$-0.17	$-0.07
High Forecast	$0.01	$0.01	$0.02	$-0.02	$0.02	$0.01	$-0.03	$-0.04	$-0.07	$-0.10	$-0.11	$-0.16	$-0.37	$-0.48	$-0.81	$-0.99	$-0.99	$-0.82	$-0.88	$-0.99	$-0.94	$-1.10	$-1.54	$-1.43	$-1.36	$-1.76	$-1.84	$-1.98	$-0.14	$-0.06
Low Forecast	$0.01	-	$0.01	$-0.02	$0.01	$0.01	$-0.04	$-0.04	$-0.07	$-0.11	$-0.13	$-0.17	$-0.41	$-0.48	$-0.81	$-0.99	$-0.99	$-0.82	$-0.88	$-0.99	$-0.94	$-1.10	$-1.54	$-1.43	$-1.36	$-1.76	$-1.84	$-1.98	$-0.20	$-0.08
Surprise %	-	-	-	-	-	-	-	-	-	0.65%	-	0.79%	0.62%	0.91%	0.77%	0.91%	4.14%	1.08%	1.12%	0.92%	0.00%	1.02%	0.71%	0.91%	0.92%	0.77%	1.06%	0.84%	8.24%	14.70%

According to undefined Wall Street analysts, Rockwell Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RMTI previous annual EPS of $NaN (undefined).

Rockwell Medical Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PROC	Procaps Group	-	-	800.90%
RMTI	Rockwell Medical	-	-	309.09%	Buy
EVOK	Evoke Pharma	-	-	300.00%	Buy
KMDA	Kamada	-	-	241.88%
AQST	Aquestive Therapeutics	-	-	127.27%	Buy
ANIP	ANI Pharmaceuticals	-	-	41.42%	Buy
COLL	Collegium Pharmaceutical	-	-	33.18%	Buy
ITCI	Intra-Cellular Therapies	-	-	10.59%	Buy
LFCR	Lifecore Biomedical	-	-	-6.88%	Buy
PAHC	Phibro Animal Health	-	-	-21.42%	Buy
AGRX	Agile Therapeutics	-	-	-33.77%	Buy
GHSI	Guardion Health Sciences	-	-	-99.69%	Buy

RMTI Forecast FAQ

Is Rockwell Medical a good buy?

Yes, according to 1 Wall Street analysts, Rockwell Medical (RMTI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of RMTI's total ratings.

What is RMTI's price target?

Rockwell Medical (RMTI) average price target is $9 with a range of $9 to $9, implying a 309.09% from its last price of $2.2. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Rockwell Medical stock go up soon?

According to Wall Street analysts' prediction for RMTI stock, the company can go up by 309.09% (from the last price of $2.2 to the average price target of $9), up by 309.09% based on the highest stock price target, and up by 309.09% based on the lowest stock price target.

Can Rockwell Medical stock reach $3?

RMTI's average twelve months analyst stock price target of $9 supports the claim that Rockwell Medical can reach $3 in the near future.

What are Rockwell Medical's analysts' financial forecasts?

Rockwell Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $95.19M (high $97.12M, low $93.26M), average EBITDA is $-30.549M (high $-29.009M, low $-32.089M), average net income is $-7.534M (high $-5.985M, low $-9.083M), average SG&A $28.28M (high $29.47M, low $27.09M), and average EPS is $-0.05 (high $-0.0445, low $-0.0555). RMTI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $93.02M (high $96.95M, low $89.1M), average EBITDA is $-31.073M (high $-29.762M, low $-32.383M), average net income is $324.2K (high $413.06K, low $235.35K), average SG&A $30.35M (high $31.63M, low $29.07M), and average EPS is $0.01 (high $0.0127, low $0.00726).

Did the RMTI's actual financial results beat the analysts' financial forecasts?

Based on Rockwell Medical's last annual report (Dec 2023), the company's revenue was $83.61M, beating the average analysts forecast of $82.67M by 1.14%. Apple's EBITDA was $-6.67M, missing the average prediction of $-27.651M by -75.88%. The company's net income was $-8.439M, missing the average estimation of $-17.275M by -51.15%. Apple's SG&A was $14.27M, missing the average forecast of $25.34M by -43.70%. Lastly, the company's EPS was $-0.0004, missing the average prediction of $-0.46 by -99.91%. In terms of the last quarterly report (Sep 2023), Rockwell Medical's revenue was $23.77M, beating the average analysts' forecast of $22.85M by 4.05%. The company's EBITDA was $-1.737M, missing the average prediction of $-7.631M by -77.24%. Rockwell Medical's net income was $-1.872M, missing the average estimation of $-3.404M by -45.01%. The company's SG&A was $3.44M, missing the average forecast of $7.45M by -53.79%. Lastly, the company's EPS was $-0.068, missing the average prediction of $-0.105 by -35.24%